About: Effect of oral L-Glutamine supplementation on Covid-19 treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of oral L-Glutamine supplementation on Covid-19 treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effect of oral L-Glutamine supplementation on Covid-19 treatment
Creator	Cengiz, Mahir Ikitimur, Hande Ozcan, Erkan Uysal, Betul Yavuzer, Serap Yavuzer, Hakan Aktepe, Emre Islamoğlu, Sami
Source	Elsevier; Medline; PMC
abstract	Summary Objectives The aim of this study is to investigate the effect of oral L-Glutamine supplementation on hospitalization time, need for intensive care unit and Coronavirus Disease-19 (Covid-19) mortality. Methods The study included 30 Covid-19 patients using L-Glutamine and 30 Covid-19 patients who did not use L-Glutamine with similar age, gender and clinical status. Diagnostic tests, laboratory examinations, clinical findings and computed thorax tomography imaging of the patients were evaluated. Results Hospitalization time was 10.4 ± 1.9 days in Covid-19 without L-Glutamine group and 8.9 ± 1.8 days in Covid-19 with L-Glutamine group (p = 0.005). In Covid-19 without the L-Glutamine group, the requirement of the intensive care unit was significantly higher (p = 0.038). Conclusions In Covid-19 cases, nutritional assessments of patients should not be overlooked in addition to the currently used treatments. Some nutritional supplements provide immune nutritional support by inhibition of inflammatory responses and regulation of immune functions in infectious diseases. Larger-scale studies are needed on L-Glutamine, which is added to normal nutrition in the early period of infection, may lead to shortened hospital stay and lead to less need for intensive care.
has issue date	2020-07-29(xsd:dateTime)
bibo:doi	10.1016/j.yclnex.2020.07.003
bibo:pmid	32835086
has license	els-covid
sha1sum (hex)	c38142a089beccdd9040f7947c042f91f95b131d
schema:url	https://doi.org/10.1016/j.yclnex.2020.07.003
resource representing a document's title	Effect of oral L-Glutamine supplementation on Covid-19 treatment
has PubMed Central identifier	PMC7387270
has PubMed identifier	32835086
schema:publication	Clin Nutr Exp
resource representing a document's body	covid:c38142a089beccdd9040f7947c042f91f95b131d#body_text
is schema:about of	named entity 'immune' named entity 'intensive care unit' named entity 'Covid-19' named entity 'HOSPITALIZATION TIME' named entity 'ORAL' named entity 'shortened' named entity 'time' named entity 'addition' named entity 'intensive care unit' named entity 'nutritional supplements' named entity 'Covid-19' named entity 'Glutamine' named entity 'Thorax CT' named entity 'oncology' named entity 'delirium' named entity 'nitrogen' named entity 'amino acids' named entity 'alanine' named entity 'glutathione' named entity 'cerebrovascular disease' named entity 'adipose tissue' named entity 'clinical symptoms' named entity 'lower respiratory tract' named entity '3, 4' named entity 'glutamine' named entity 'Serum' named entity 'skeletal muscle' named entity 'L-Glutamine' named entity 'enteral' named entity 'lactate dehydrogenase' named entity 'Hsp70' named entity 'alcoholism' named entity 'morbidity' named entity 'nutrition' named entity 'skeletal muscle' named entity 'L-Glutamine' named entity 'kidney' named entity 'L-Glutamine' named entity 'cysteine' named entity 'intracellular' named entity 'potassium' named entity 'lower respiratory tract' named entity 'catabolic process' named entity 'L-Glutamine' named entity 'Declaration of Helsinki' named entity 'lopinavir' named entity 'lower respiratory tract' named entity 'parenterally' named entity 'glutamine' named entity 'remdesivir' named entity 'antiviral agents' named entity 'heat shock proteins' named entity 'L-Glutamine' named entity 'dividing cells' named entity 'Parkinson's disease' named entity 'morbidity' named entity 'oropharyngeal' named entity 'Kolmogorov-Smirnov test' named entity 'protein' named entity 'acute respiratory failure' named entity 'RNA' named entity 'malnutrition' named entity 'amino acid' named entity 'Glutamine' named entity 'Chicago' named entity 'Leukocytes' named entity 'sepsis' named entity 'Covid19' named entity 'Nestle' named entity 'written consent' named entity 'lungs' named entity 'cardiovascular diseases' named entity 'COVID' named entity 'biochemical'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software